Extracellular histone release in response to traumatic injury: Implications for a compensatory role of activated protein C

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 6, 2012, Pages 1389-1394

  Kutcher, Matthew E ^a   Xu, Jun ^b   Vilardi, Ryan F ^a   Ho, Coral ^a   Esmon, Charles T ^b,c   Cohen, Mitchell Jay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

DAMPs; histones; protein C; Trauma

Indexed keywords

ACTIVATED PROTEIN C; D DIMER; HISTONE; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE LUNG INJURY; ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CRITICALLY ILL PATIENT; ENZYME BLOOD LEVEL; EXTRACELLULAR SPACE; GLASGOW COMA SCALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INJURY; INJURY SEVERITY; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; RESUSCITATION;

ACUTE LUNG INJURY; ADULT; BIOLOGICAL MARKERS; HISTONES; HUMANS; INJURY SEVERITY SCORE; INTERNATIONAL NORMALIZED RATIO; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTEIN C; TIME FACTORS; TRAUMA CENTERS; WOUNDS AND INJURIES;

EID: 84871196677     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318270d595     Document Type: Article

References (64)

1. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-430.
2. Zeerleder S, Zwart B,WuilleminWA, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med. 2003;31:1947-1951.
3. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535.
4. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15:1318-1321.
5. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880-15885.
6. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118:1952-1961.
7. Xu J, Zhang X, Monestier M, et al. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011;187:2626-2631.
8. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32(suppl 1):49-60.
9. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9:338-342.
10. Yuksel M, Okajima K, Uchiba M, et al. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost. 2002;88:267-273.
11. Esmon CT. Protein C pathway in sepsis. Ann Med. 2002;34:598-605.
12. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104-107.
13. Chesebro BB, Rahn P, Carles M, et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock. 2009;32:659-665.
14. Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg. 2011;255:379-385.
15. Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion, modulated through the protein C pathway? Ann Surg. 2007;245:812-818.
16. Baker SP, O'Neill B, Haddon W Jr, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187-196.
17. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149(Pt 1):818-824.
18. Sauaia A, Moore EE, Johnson JL, et al. Validation of postinjury multiple organ failure scores. Shock. 2009;31:438-447.
19. Lo YM, Rainer TH, Chan LY, et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem. 2000;46:319-323.
20. Lam NY, Rainer TH, Chan LY, et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. 2003;49:1286-1291.
21. Johansson PI, Sorensen AM, Perner A, et al. High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. J Thromb Haemost. 2011.
22. Johansson PI, Stensballe J, Rasmussen LS, et al. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254:194-200.
23. Tsujimoto H, Ono S, Efron PA, et al. Role of Toll-like receptors in the development of sepsis. Shock. 2008;29:315-321.
24. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774-780.
25. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26:174-179.
26. Li Y, Xiang M, Yuan Y, et al. Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1670-R1680.
27. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13:R174.
28. Peltz ED, Moore EE, Eckels PC, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock. 2009;32:17-22.
29. Barochia A, Solomon S, Cui X, et al. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol. 2011;7:479-494.
30. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. J Immunol. 2008;180:1895-1902.
31. Neeli I, Dwivedi N, Khan S, et al. Regulation of extracellular chromatin release from neutrophils. J Innate Immun. 2009;1:194-201.
32. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009;30:513-521.
33. Li Y, Liu B, Fukudome EY, et al. Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide- induced shock. Surgery. 2011;150:442-451.
34. Li Y, Liu B, Fukudome EY, et al. Surviving lethal septic shock without fluid resuscitation in a rodent model. Surgery. 2010;148:246-254.
35. Li Y, Liu B, Zhao H, et al. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock. 2009; 32:517-523.
36. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
37. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296: 1880-1882.
38. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003; 373(Pt 1):65-70.
39. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204:2439-2448.
40. Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion, modulated through the protein C pathway? Ann Surg. 2007;245:812-818.
41. Baker SP, O'Neill B, Haddon W Jr, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187-196.
42. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149(Pt 1):818-824.
43. Sauaia A, Moore EE, Johnson JL, et al. Validation of postinjury multiple organ failure scores. Shock. 2009;31:438-447.
44. Lo YM, Rainer TH, Chan LY, et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem. 2000;46:319-323.
45. Lam NY, Rainer TH, Chan LY, et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. 2003;49:1286-1291.
46. Johansson PI, Sorensen AM, Perner A, et al. High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. J Thromb Haemost. 2011.
47. Johansson PI, Stensballe J, Rasmussen LS, et al. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254:194-200.
48. Tsujimoto H, Ono S, Efron PA, et al. Role of Toll-like receptors in the development of sepsis. Shock. 2008;29:315-321.
49. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009;15:774-780.
50. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26:174-179.
51. Li Y, Xiang M, Yuan Y, et al. Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1670-R1680.
52. Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13:R174.
53. Peltz ED, Moore EE, Eckels PC, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock. 2009;32:17-22.
54. Barochia A, Solomon S, Cui X, et al. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol. 2011;7:479-494.
55. Neeli I, Khan SN, Radic M. Histone deimination as a response to inflammatory stimuli in neutrophils. J Immunol. 2008;180:1895-1902.
56. Neeli I, Dwivedi N, Khan S, et al. Regulation of extracellular chromatin release from neutrophils. J Innate Immun. 2009;1:194-201.
57. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old weapons. Trends Immunol. 2009;30:513-521.
58. Li Y, Liu B, Fukudome EY, et al. Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide- induced shock. Surgery. 2011;150:442-451.
59. Li Y, Liu B, Fukudome EY, et al. Surviving lethal septic shock without fluid resuscitation in a rodent model. Surgery. 2010;148:246-254.
60. Li Y, Liu B, Zhao H, et al. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock. 2009; 32:517-523.
61. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
62. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296: 1880-1882.
63. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003; 373(Pt 1):65-70.
64. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204:2439-2448.